Imagine you are building a precision fermentation startup. You have the strain, the bioprocess, and the seed funding to begin. You are ready to run your first bioreactor cycle and you realise that before a single fermentation can proceed, the vessel must be sterilised. The industry standard is Steam-in-Place (SIP): saturated steam at 121°C and 15 psi, injected directly into the bioreactor and its associated pipework for a defined exposure period.

SIP requires a boiler. A boiler requires installation, certification, ongoing maintenance, and a qualified technician. In the shared R&D space you have just signed a lease on, none of these exist.

This is the moment many teams discover that the real cost of starting a fermentation process is not in the biology. It is in the infrastructure. And it is a cost that rarely appears in business plans, pitch decks, or early-stage equipment budgets.

This article examines why Steam-in-Place has become a structural bottleneck for early-stage biotech, reviews the evidence supporting a bioreactor sterilization alternative to SIP based on vaporised hydrogen peroxide (VHP), and presents data from a real-world validation study conducted under industrial conditions at pilot scale.

The barrier to entry in precision fermentation is not scientific. It is steam.

1. Steam-in-Place: Efficacy, Infrastructure, and Cost

SIP achieves sterilisation through thermal inactivation. At 121°C, the reference temperature for moist heat sterilisation per ISO 17665-1:2006, a 15-minute exposure achieves a Sterility Assurance Level (SAL) of 10⁻⁶, a 6-log reduction in microbial bioburden, including bacterial endospores.

For large-scale industrial fermentation, where bioreactors of thousands of litres operate continuously within permanently installed facilities, this method is well-suited and cost-effective at scale. The challenge arises at the laboratory and pilot scale that characterises most early-stage fermentation ventures. At this scale, the infrastructure requirements of SIP become disproportionate. A systematic analysis of the cost components reveals five distinct barriers:

• Steam generation capital cost: Acquisition of a dedicated steam generator or access to a centralised boiler system typically ranges from €15,000 to over €150,000.
• Distribution infrastructure: Stainless steel steam pipework, control valves, and steam traps must be designed and installed by specialist contractors.
• Qualified operation: Pressurised steam systems require operators with specific competencies and safety compliance.
• Energy intensity: Steam generation is thermodynamically expensive, consuming significant thermal energy to raise water to boiling point.
• Cycle duration: A complete SIP cycle typically requires several hours, reducing bioreactor utilisation rates.

1.1 The Hidden Barrier in Precision Fermentation Facility Design

Steam system design is typically determined early in the facility planning process. Once installed, steam infrastructure constrains facility layout and bioreactor selection. Teams that choose a facility without steam capability and subsequently require SIP face either costly retrofitting or process constraints.

2. The Bioeconomy Paradox: Advanced Biology, Legacy Infrastructure

Precision fermentation is central to the emerging bioeconomy, producing alternative proteins, biofertilisers, and pharmaceutical intermediates. However, the rate of progress in biological sciences has substantially outpaced the development of enabling infrastructure.

DNA synthesis costs fell by orders of magnitude over two decades. Bioreactor sterilization still depends on the same boiler technology from the 1950s.

What the new bioeconomy requires is a bioreactor sterilization alternative to SIP that matches the flexibility, portability, and cost profile of modern bioprocess equipment, without compromising on efficacy or regulatory standing.

3. Vaporised Hydrogen Peroxide as a Bioreactor Sterilization Alternative

Vaporised hydrogen peroxide (VHP) is an established chemical sterilant with a multi-decade history of use in pharmaceutical manufacturing. Its antimicrobial mechanism is based on the generation of reactive oxygen species (ROS), principally hydroxyl radicals (•OH), that oxidise nucleic acids and membrane lipids.

In January 2024, the FDA elevated VHP to Established Category A sterilisation status for medical devices, recognising it alongside moist heat and ethylene oxide. VHP is also registered with the US EPA as a sporicidal sterilant and complies with ISO 22441:2022.

3.1 The DeloxHP Formulation: Controlled VHP Generation

The DeloxHP technology, developed by Delox, generates VHP from a solid-state precursor with defined release kinetics. This design eliminates the requirement for handling concentrated aqueous hydrogen peroxide solutions, which present corrosion and safety hazards. The system is self-contained, operates without steam, and requires only standard electrical supply.

4. Real-World Validation: Food4Sustainability CoLAB (2025)

In 2025, the DeloxHP technology was implemented and validated at the Food4Sustainability CoLAB R&D unit in Nazaré, Portugal. The validation was conducted under real operational conditions at pilot scale.

4.1 Energy Consumption Results

Engineering measurements confirmed a reduction of up to 72% in energy consumption per sterilisation cycle using the DeloxHP system compared to equivalent steam-based SIP. This reduction reflects the elimination of steam generation, replacing it with a VHP process that operates at ambient temperature.

A 72% reduction in energy per sterilisation cycle, validated under real industrial conditions at pilot scale, not a laboratory projection.

5. Implications for Early-Stage Precision Fermentation Operations

• Infrastructure independence: Elimination of the steam generation requirement removes the largest single infrastructure investment.
• Installation timeline: The time from facility decision to first operable cycle is substantially compressed.
• Location flexibility: Operations can be established in shared research infrastructure or science parks that lack dedicated utility systems.
• Modular scalability: Capacity can be added incrementally without resizing a centralised steam system.
• Sustainability metrics: A 72% reduction in energy consumption directly supports environmental sustainability reporting and EU funding eligibility.

6. The Question That Should Be Asked Earlier

The more productive approach is to include sterilisation methodology explicitly in the facility design question set from the outset: “Is steam-based sterilisation actually required for this process and this scale?”

The right question is not ‘how do I install SIP?’. It is ‘do I need steam at all?’

7. Conclusion

The evidence demonstrates that a validated bioreactor sterilization alternative to SIP, based on vaporised hydrogen peroxide and delivered via the DeloxHP formulation, achieves equivalent sterilisation efficacy at SAL 10⁻⁶ while reducing energy consumption by 72%.

Frequently Asked Questions

What is a bioreactor sterilization alternative to Steam-in-Place (SIP)?

Vaporised hydrogen peroxide (VHP) is the most extensively validated alternative to SIP for bioreactor sterilization. Unlike SIP, VHP-based systems are self-contained, portable, and require only standard electrical supply.

Is VHP sterilization as effective as steam?

Yes. VHP achieves a Sterility Assurance Level (SAL) of 10⁻⁶, which is the same standard required for medical and pharmaceutical sterilization, including the inactivation of resistant bacterial spores like Geobacillus stearothermophilus.

Does VHP leave toxic residues in the bioreactor?

No. Hydrogen peroxide decomposes entirely into water vapour and molecular oxygen, leaving no toxic residues and requiring no chemical neutralisation.